During the last session, Pacific Biosciences of California Inc (NASDAQ:PACB)’s traded shares were 6.26 million, with the beta value of the company hitting 2.01. At the end of the trading day, the stock’s price was $1.27, reflecting an intraday loss of -3.05% or -$0.04. The 52-week high for the PACB share is $3.89, that puts it down -206.3 from that peak though still a striking 8.66% gain since the share price plummeted to a 52-week low of $1.16. The company’s market capitalization is $378.28M, and the average intraday trading volume over the past 10 days was 7.3 million shares, and the average trade volume was 11.14 million shares over the past three months.
Pacific Biosciences of California Inc (PACB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.19. PACB has a Sell rating from 1 analyst(s) out of 11 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it.
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Pacific Biosciences of California Inc (PACB) registered a -3.05% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.05% in intraday trading to $1.27, hitting a weekly high. The stock’s 5-day price performance is 1.60%, and it has moved by -18.59% in 30 days. Based on these gigs, the overall price performance for the year is -65.49%. The short interest in Pacific Biosciences of California Inc (NASDAQ:PACB) is 53.41 million shares and it means that shorts have 3.95 day(s) to cover.
The consensus price target of analysts on Wall Street is $3, which implies an increase of 57.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $4 respectively. As a result, PACB is trading at a discount of -214.96% off the target high and -57.48% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.55%. While earnings are projected to return 33.69% in 2025, the next five years will return 24.02% per annum.
PACB Dividends
Pacific Biosciences of California Inc is due to release its next quarterly earnings on 2025-Feb-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Pacific Biosciences of California Inc (NASDAQ:PACB)’s Major holders
Pacific Biosciences of California Inc insiders own 8.84% of total outstanding shares while institutional holders control 78.25%, with the float percentage being 85.83%. ARK INVESTMENT MANAGEMENT LLC is the largest shareholder of the company, while 315.0 institutions own stock in it. As of 2024-06-30, the company held over 33.21 million shares (or 12.1932% of all shares), a total value of $45.5 million in shares.
The next largest institutional holding, with 26.0 million shares, is of VANGUARD GROUP INC’s that is approximately 9.6443% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $35.62 million.
Also, the Mutual Funds coming in first place with the largest holdings of Pacific Biosciences of California Inc (PACB) shares are ARK Innovation ETF and ARK Genomic Revolution ETF . Data provided on Feb 28, 2025 indicates that ARK Innovation ETF owns about 21.43 shares. This amounts to just over 7.20 percent of the company’s overall shares, with a $27.22 million market value. The same data shows that the other fund manager holds slightly less at 13.1, or about 4.40% of the stock, which is worth about $16.64 million.
